Review published: 20 November 2015 doi: 10.3389/fendo.2015.00176
Molecular Targeted Therapies of Aggressive Thyroid Cancer Silvia Martina Ferrari1 , Poupak Fallahi1 , Ugo Politti1 , Gabriele Materazzi2 , Enke Baldini3 , Salvatore Ulisse3 , Paolo Miccoli2 and Alessandro Antonelli1* Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2 Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy, 3 Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy 1
Edited by: Rauf Latif, Mount Sinai School of Medicine, USA Reviewed by: Xuguang Zhu, National Institutes of Health, USA Yuji Nagayama, Nagasaki University, Japan *Correspondence: Alessandro Antonelli [email protected] Specialty section: This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology Received: 10 September 2015 Accepted: 02 November 2015 Published: 20 November 2015 Citation: Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P and Antonelli A (2015) Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front. Endocrinol. 6:176. doi: 10.3389/fendo.2015.00176
Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], while medullary thyroid cancer (MTC) accounts 90% of TC and are subdivided into PTC (~90%) or FTC (~10%); (2) medullary thyroid cancer (MTC) accounts
Molecular Targeted Therapies of Aggressive Thyroid Cancer Silvia Martina Ferrari1 , Poupak Fallahi1 , Ugo Politti1 , Gabriele Materazzi2 , Enke Baldini3 , Salvatore Ulisse3 , Paolo Miccoli2 and Alessandro Antonelli1* Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2 Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy, 3 Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy 1
Edited by: Rauf Latif, Mount Sinai School of Medicine, USA Reviewed by: Xuguang Zhu, National Institutes of Health, USA Yuji Nagayama, Nagasaki University, Japan *Correspondence: Alessandro Antonelli [email protected] Specialty section: This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology Received: 10 September 2015 Accepted: 02 November 2015 Published: 20 November 2015 Citation: Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P and Antonelli A (2015) Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front. Endocrinol. 6:176. doi: 10.3389/fendo.2015.00176
Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], while medullary thyroid cancer (MTC) accounts 90% of TC and are subdivided into PTC (~90%) or FTC (~10%); (2) medullary thyroid cancer (MTC) accounts
